| CAS: | 100299-08-9 | ||||||||
| 中文名称: |
| ||||||||
| 英文名称: |
|
| 货号 | 品牌 | 产品名称 | 规格 | 包装、参考价格 | 详情 | ||||||||||||||||||||||||||||||||||||||||||||||||
| P2547 | TCI | Pemirolast Potassium | >98.0%(T)(HPLC) | 505元/1G; 1725元/5G; | 展开 | ||||||||||||||||||||||||||||||||||||||||||||||||
基本信息
技术规格
物性(参考值)
安全信息
相关法规
| |||||||||||||||||||||||||||||||||||||||||||||||||||||
| 904270 | J&K | Pemirolast Potassium | 98%, 是H1组胺受体拮抗剂和肥大细胞稳定剂,可作为抗过敏化合物 | 461元/1G; 1439元/5G; | 展开 | ||||||||||||||||||||||||||||||||||||||||||||||||
基本信息
产品描述 Pemirolast potassium是一种组胺H1拮抗剂和肥大细胞稳定剂,用作抗过敏药。 靶点(IC50 & Targe) H1 receptor 体外研究 Pemirolast potassium (BMY 26517)是一种新型口服,非支气管扩张抗过敏药物,用于治疗哮喘。[1] Pemirolast potassium (BMY 26517)抑制化学介质从组织肥大细胞的释放,并且能够抑制多肽,包括P物质,[2]神经激肽(NK) A,以及降钙素基因相关肽(CGRP)从感觉神经的释放。[3] Pemirolast potassium被用于治疗过敏性结膜炎,并预防药物,如紫杉醇引起的肺过敏反应。[4] 体内研究 Pemirolast potassium (BMY 26517)通过抑制大鼠体内P物质的释放减少高岭土的摄入。[2] 在大鼠体内,Pemirolast通过抑制感觉神经肽的释放能够有效减弱紫杉醇过敏反应。[3] 参考文献 [1] Kemp JP, et al. Ann Allergy, 1992, 68(6), 488-491. [2] Tatsushima Y, et al. Eur J Pharmacol, 2011, 661(1-3), 57-62. [3] Itoh Y, et al. Neuropharmacology, 2004, 46(6), 888-894. [4] Abelson MB, et al. J Ocul Pharmacol Ther, 2002, 18(5), 475- 安全信息
| |||||||||||||||||||||||||||||||||||||||||||||||||||||
| SML0107 | Sigma-Aldrich | Pemirolast Potassium | ≥98% (HPLC) | 1210.57元/10 MG; | 展开 | ||||||||||||||||||||||||||||||||||||||||||||||||
产品说明 包装 10, 50 mg in glass bottle 生化/生理作用 Pemirolast potassium is a histamine H1 antagonist and mast cell stabilizer that acts as an antiallergic agent. It Inhibits chemical mediator release from tissue mast cells and has recently also been shown to inhibit the release of peptides including substance P, neurokinin (NK) A, and calcitonin gene-related peptide (CGRP) from sensory nerves. It has been used for the treatment of allergic conjunctivitis prophylaxis of for pulmonary hypersensitivity reactions to drugs such as paclitaxel 特点和优势 This compound was developed by Bristol-Myers Squibb. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here. 基本信息
产品性质
安全信息
| |||||||||||||||||||||||||||||||||||||||||||||||||||||